Literature DB >> 18347932

Tumor characteristics in screen-detected and symptomatic breast cancers.

István Pálka1, Gyöngyi Kelemen, Katalin Ormándi, György Lázár, Tibor Nyári, László Thurzó, Zsuzsanna Kahán.   

Abstract

The natural course of early breast cancer has changed as a result of the introduction of mammographic screening. The present aim was a prospective analysis of screen-detected and symptomatic operable breast cancers in the era of mammographic service screening. The mode of detection (screen-detected, symptomatic or interval cancer), the type of mammographic image and other characteristics (the invasive tumor size, histological tumor type, grade, nodal, hormone receptor and HER2 status and the presence of lymphovascular invasion) of 569 invasive breast cancers were studied. Screen-detected cancers were significantly more frequently of grade I, < 10 mm of size and node-negative (p < 0.001, respectively). Symptomatic/interval cancers were significantly more frequently of grade 3, >20 mm of size (p < 0.001), and exhibited lymphovascular invasion (p = 0.001). Screening-detection of the tumor favored breast-conserving surgery, sentinel lymph node biopsy and the avoidance of chemotherapy (p < 0.001). Cancers associated with casting-type calcifications on the mammogram were typically of ductal type (p = 0.043), of grade 2-3, estrogen receptor and progesterone receptor-negative and HER2-positive (p < 0.001). Interval cancers occurred significantly more often at a younger age and remained mammographically occult as compared with other cancers. Mammographic screen-detected cancers demonstrate more favorable prognostic features, and need less extensive treatment than symptomatic or interval cancers. The mammographic appearance of the tumor reflects its biological behavior, and this should be considered in the management optimization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347932     DOI: 10.1007/s12253-008-9010-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  29 in total

1.  Quality assurance in the diagnosis of breast disease. EUSOMA Working Party.

Authors:  N M Perry
Journal:  Eur J Cancer       Date:  2001-01       Impact factor: 9.162

2.  Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis.

Authors:  Kathleen A Cronin; Eric J Feuer; Lauren D Clarke; Sylvia K Plevritis
Journal:  J Natl Cancer Inst Monogr       Date:  2006

3.  Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data.

Authors: 
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-01       Impact factor: 4.254

4.  Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers.

Authors:  M Crosier; D Scott; R G Wilson; C D Griffiths; F E May; B R Westley
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

5.  Biologic characteristics of interval and screen-detected breast cancers.

Authors:  F D Gilliland; N Joste; P M Stauber; W C Hunt; R Rosenberg; G Redlich; C R Key
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

6.  Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.

Authors:  Yu Shen; Ying Yang; Lurdes Y T Inoue; Mark F Munsell; Anthony B Miller; Donald A Berry
Journal:  J Natl Cancer Inst       Date:  2005-08-17       Impact factor: 13.506

7.  Risk for distant recurrence of breast cancer detected by mammography screening or other methods.

Authors:  Heikki Joensuu; Tiina Lehtimäki; Kaija Holli; Liisa Elomaa; Taina Turpeenniemi-Hujanen; Vesa Kataja; Ahti Anttila; Mikael Lundin; Jorma Isola; Johan Lundin
Journal:  JAMA       Date:  2004-09-01       Impact factor: 56.272

8.  Significant improvement in breast cancer survival through population-based mammography screening.

Authors:  Pekka J Klemi; Ilmo Parvinen; Liisa Pylkkänen; Lea Kauhava; Pirjo Immonen-Räihä; Osmo Räsänen; Hans Helenius
Journal:  Breast       Date:  2003-10       Impact factor: 4.380

9.  Mammographic casting-type calcification associated with small screen-detected invasive breast cancers: is this a reliable prognostic indicator?

Authors:  C Peacock; R M Given-Wilson; S W Duffy
Journal:  Clin Radiol       Date:  2004-02       Impact factor: 2.350

10.  Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening.

Authors:  Miranda F Ernst; Adri C Voogd; Jan Willem W Coebergh; Jan A Roukema
Journal:  Cancer       Date:  2004-04-01       Impact factor: 6.860

View more
  12 in total

1.  Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.

Authors:  N Kobayashi; M Hikichi; K Ushimado; A Sugioka; Y Kiriyama; M Kuroda; T Utsumi
Journal:  Clin Transl Oncol       Date:  2017-04-13       Impact factor: 3.405

2.  Mammographic density and hormone receptor expression in breast cancer: the Multiethnic Cohort Study.

Authors:  Shannon M Conroy; Ian Pagano; Laurence N Kolonel; Gertraud Maskarinec
Journal:  Cancer Epidemiol       Date:  2011-01-17       Impact factor: 2.984

3.  Organized screening detects breast cancer at earlier stage regardless of molecular phenotype.

Authors:  Claire M B Holloway; Li Jiang; Marlo Whitehead; Jennifer M Racz; Patti A Groome
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-16       Impact factor: 4.553

4.  Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening.

Authors:  A Caldarella; D Puliti; E Crocetti; S Bianchi; V Vezzosi; P Apicella; M Biancalani; A Giannini; C Urso; F Zolfanelli; E Paci
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-09       Impact factor: 4.553

5.  The burden of breast cancer in Italy: mastectomies and quadrantectomies performed between 2001 and 2008 based on nationwide hospital discharge records.

Authors:  Prisco Piscitelli; Maddalena Barba; Massimo Crespi; Massimo Di Maio; Antonio Santoriello; Massiliamo D'Aiuto; Alfredo Fucito; Arturo Losco; Francesca Pentimalli; Pasquale Maranta; Giovanna Chitano; Alberto Argentiero; Cosimo Neglia; Alessandro Distante; Gian Luca Di Tanna; Maria Luisa Brandi; Alfredo Mazza; Ignazio R Marino; Antonio Giordano
Journal:  J Exp Clin Cancer Res       Date:  2012-11-20

6.  Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients.

Authors:  Amir Bahrami-Ahmadi; Fariborz Makarian; Mohammad R Mortazavizadeh; Mohammad F Yazdi; Mehdi Chamani
Journal:  J Res Med Sci       Date:  2012-09       Impact factor: 1.852

7.  Long-term prognosis of breast cancer detected by mammography screening or other methods.

Authors:  Tiina Lehtimäki; Mikael Lundin; Nina Linder; Harri Sihto; Kaija Holli; Taina Turpeenniemi-Hujanen; Vesa Kataja; Jorma Isola; Heikki Joensuu; Johan Lundin
Journal:  Breast Cancer Res       Date:  2011-12-28       Impact factor: 6.466

8.  Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers.

Authors:  M Ángeles López-García; Irene Carretero-Barrio; Belén Pérez-Míes; Miguel Chiva; Carolina Castilla; Begoña Vieites; José Palacios
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

9.  Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series.

Authors:  Anna Crispo; Maddalena Barba; Giuseppe D'Aiuto; Michelino De Laurentiis; Maria Grimaldi; Massimo Rinaldo; Giuseppina Caolo; Massimiliano D'Aiuto; Immacolata Capasso; Emanuela Esposito; Alfonso Amore; Maurizio Di Bonito; Gerardo Botti; Maurizio Montella
Journal:  BMC Cancer       Date:  2013-01-10       Impact factor: 4.430

10.  Breast cancer screening of mutation carriers in the era of COVID-19 pandemic.

Authors:  Angela Toss; Matteo Lambertini; Kevin Punie; Giovanni Grandi; Laura Cortesi
Journal:  Int J Cancer       Date:  2020-07-01       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.